Production (Stage)
Goldenwell Biotech, Inc.
GWLL
$0.20
$0.000.00%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -114.29% | -94.74% | -95.24% | -98.90% | -98.57% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -114.29% | -94.74% | -95.24% | -98.90% | -98.57% |
| Cost of Revenue | -100.00% | -100.00% | -80.00% | -98.14% | -98.28% |
| Gross Profit | 100.00% | -100.00% | -130.00% | -100.42% | -100.39% |
| SG&A Expenses | 11.96% | 4.03% | -88.06% | -86.72% | -89.00% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.46% | 2.97% | -88.05% | -86.96% | -89.20% |
| Operating Income | -11.87% | -4.58% | 88.03% | 86.40% | 88.71% |
| Income Before Tax | -17.41% | -12.10% | 87.66% | 86.03% | 88.34% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -17.41% | -12.10% | 87.66% | 86.03% | 88.34% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.41% | -12.10% | 87.66% | 86.03% | 88.34% |
| EBIT | -11.87% | -4.58% | 88.03% | 86.40% | 88.71% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -8.33% | -8.33% | 86.96% | 84.27% | 86.52% |
| Normalized Basic EPS | -14.29% | -14.29% | 87.72% | 85.45% | 87.27% |
| EPS Diluted | -8.33% | -8.33% | 86.96% | 84.27% | 86.52% |
| Normalized Diluted EPS | -14.29% | -14.29% | 87.72% | 85.45% | 87.27% |
| Average Basic Shares Outstanding | 0.00% | 0.65% | -0.62% | 0.66% | 1.98% |
| Average Diluted Shares Outstanding | 0.00% | 0.65% | -0.62% | 0.66% | 1.98% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |